PATENT CLAIM ANALYSIS

Application Number: 15770569
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "468000"]

Abstract:
The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.

Claim (Index 10):
The oral enteric high-dose tablet according to  claim 9 , characterized in that the release profile in the biodissolution test of the active ingredient mesalazine of a high-dose tablet substantially corresponds to the release profile of two tablets each containing half the amount of the active ingredient of the high-dose tablet.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 91.0
- Lexical Diversity: 1.1
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13790809', '15536334', '13951951', '10360410', '12236157']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7017742552935985
- 35 USC 102 Novelty (BERT): 0.5027067638428954
- Combined Prediction Score: 0.6818675061485282
- Mean Citation Score: 198.664118
- Max Citation Score: 203.6724
- Similarity Product: 125.61539012203215

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test